<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754180</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-1015</org_study_id>
    <nct_id>NCT02754180</nct_id>
  </id_info>
  <brief_title>Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes</brief_title>
  <official_title>Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With
      R1 Resection and/or Positive Lymph Nodes after curative resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjuvant Gemcitabine Versus Gemcitabine With TS-1 based Chemoradiation in Pancreatic
      Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes after curative resection: a
      randomized phase II study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>From date of randomization until the date of first documented disease recurrence or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>from randomization to 1 month after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy with chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_label>chemotherapy with chemoradiation</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TS-1 with radiation</intervention_name>
    <description>gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.</description>
    <arm_group_label>chemotherapy with chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed resected ductal pancreatic adenocarcinoma with R1 resection
             and/or positive lymph nodes.

          -  Subject should start treatment no later than 10 weeks postsurgery.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Acceptable hematology parameters:

               -  Absolute neutrophil count ≥1500 cell/mm3

               -  Platelet count ≥100,000/mm3

               -  Hemoglobin (Hgb) ≥8.0 g/dL

          -  Acceptable blood chemistry levels:

               -  Aspartate aminotransferase (AST) and Alanine transaminase (ALT) ≤2.5 × upper
                  limit of normal range (ULN)

               -  Total bilirubin ≤ 2.5 x upper Limit of Normal (ULN)

               -  Serum creatinine within upper limits of normal.

          -  Cancer antigen (CA)19-9 ≤ 2.5 x upper Limit of Normal (ULN) assessed within 14 days of
             randomization.

          -  No disease recurrence or metastases detected on CT/MRI assessed within 30 days of
             randomization.

          -  Signed informed consent.

        Exclusion Criteria:

          -  R2 resection or presence of metastatic disease.

          -  Prior neo-adjuvant treatment or radiation therapy for pancreatic adenocarcinoma.

          -  Any other malignancy within 5 years prior to randomization, with the exception of
             adequately treated in-situ carcinoma of the cervix, uteri, bladder, or nonmelanomatous
             skin cancer.

          -  Active, uncontrolled infection(s) requiring systemic therapy, defined as ongoing
             signs/symptoms related to the infection without improvement despite appropriate
             treatment.

          -  Severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the 6 months of study registration

               -  Uncontrolled hypertension, diabetes or arrhythmia.

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization.

          -  Not able to take medicine orally.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bai Chunmei, MD</last_name>
    <phone>861069158773</phone>
    <email>baichunmei1964@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng Yuejuan, MD</last_name>
    <phone>861069158773</phone>
    <email>cnchengyuejuan@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Medical Oncology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuejuan Cheng, M.D.</last_name>
      <phone>861069158315</phone>
      <email>cnchengyuejuan@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Bai Chunmei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng Yuejuan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>YueJuan Cheng</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>adjuvant</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>R1 resection</keyword>
  <keyword>positive lymph nodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

